
CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds
Summary
CG Oncology reported successful results from its Phase 3 clinical trial evaluating cretostimogene grenadenorepvec for bladder cancer treatment. The company leadership described the positive data as a major corporate milestone, noting the therapy achieved a significant recurrence benefit during the pivotal study.
CG Oncology Inc. (NASDAQ:CGON) on Monday announced positive topline results from its Phase 3 PIVOT-006 trial, which Arthur Kuan, chairman, president, and CEO of CG Oncology, called a defining milestone for the company. Kuan stated that the data position cretostimogene grenadenorepvec as the first and only therapeutic candidate to show a significant recurrence benefit in a pivotal Phase 3 study…
Source: Read the full story at Top Stories Feed